Abstract:Background: Enterovirus 71 (EV71), a member of the Enterovirus genus of the Picornaviridae family, is one of the causative pathogens of hand-foot-and-mouth disease (HFMD) and the most common etiological agent isolated from HFMD patients complicated with neurological disorders. EV71 has become an increasingly important neurotropic enterovirus in the post-poliomyelitis eradication era. Effective antiviral agents and vaccines against this virus are currently still under development. We reviewed publications on the development of EV71 vaccines in order to provide an overview of the field. Methods: Fifty-five articles on EV71 vaccine development, published from 1974 to 2009, were collected from Sun Yat-sen University library and reviewed. Results: Various types of vaccine have been developed for EV71. In results published to date, all vaccines for EV71 under development appear to elicit an immune response in rodents or in monkeys. According to the established regulatory standards, it may be relatively easy to acquire a license to use the inactivated virus in order to meet the immediate demands for EV71 control . With regard to the attenuated vaccine, it is critical to increase the genetic stability before clinical use, due to the risk of virulent revertants. The virus-like particle (VLP) vaccine, not only conserving the conformational epitopes, but also having no risk of virulent revertants, is another promising vaccine candidate for EV71, but needs further development. The VP1 capsid protein is the backbone antigen protein for developing subunit vaccine and epitope vaccine; these remain viable potential vaccine strategies worthy of further study and development. Conclusions: The conservation of the three-dimensional structure is important for the EV71 inactivated vaccine and VLP vaccine to induce a strong immune response. To develop EV71 vaccines with a high protection efficacy, strategies such as the use of adjuvant, strong promoters, tissue-specific promoters, and addition of mucosal immune adjuvant should be considered.

EV71: an Emerging Infectious Disease Vaccine Target in the Far East?

EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)

Status of research and development of vaccines for enterovirus 71

Enterovirus A71 Vaccines

Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine

Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD)

The need for development of other enterovirus vaccines in addition to EV-A71 vaccine

Epidemiological Characteristics of Severe Hand Foot and Mouth Disease and Research Progress of Enterovirus 71 Vaccine

Enterovirus 71 vaccine: close but still far

Enterovirus-Associated Hand-Foot and Mouth Disease and Neurological Complications in Japan and the Rest of the World

Progress of Reaseach on Vaccine of Enterovirus 71

EV71 Virus-Like Particles Produced by Co-Expression of Capsid Proteins in Yeast Cells Elicit Humoral Protective Response Against EV71 Lethal Challenge

Epidemiology of Hand, Foot and Mouth Disease in China, 2008 to 2015 Prior to the Introduction of EV-A71 Vaccine

Research Progress of Enterovirus 71 Vaccines

Co-infection and enterovirus B: post EV-A71 mass vaccination scenario in China

Progress of severe hand-foot-mouth disease infected by EV71 virus

Review of hand, foot and mouth disease

Development of Novel Vaccines against Enterovirus-71

From Monovalent to Multivalent Vaccines, the Exploration for Potential Preventive Strategies Against Hand, Foot, and Mouth Disease (HFMD)

Expression and Immunogenicity of Novel Subunit Enterovirus 71 Vp1 Antigens

Recent progress and challenges in drug development to fight hand, foot and mouth disease